Precision BioSciences Inc (DTIL)vsJohnson & Johnson (JNJ)
DTIL
Precision BioSciences Inc
$7.88
+1.40%
HEALTHCARE · Cap: $204.35M
JNJ
Johnson & Johnson
$253.85
+0.00%
HEALTHCARE · Cap: $613.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 213691% more annual revenue ($96.36B vs $45.07M). JNJ leads profitability with a 21.8% profit margin vs -96.7%. JNJ earns a higher WallStSmart Score of 57/100 (C).
DTIL
Avoid33
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+72.2%
Fair Value
$14.65
Current Price
$7.88
$6.77 discount
Margin of Safety
-87.1%
Fair Value
$136.12
Current Price
$253.85
$117.73 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 37272.0% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth, Price/Book. Revenue growth of 37272.0% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
DTIL profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.28 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 33/100), backed by strong 21.8% margins. DTIL offers better value entry with a 72.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?